COMMUNIQUÉS West-GlobeNewswire

ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting
16/10/2025
Presentation at AAO 2025 part of ongoing NEW DAY data dissemination at medical meetings PRINCETON, N.J., Oct. 16, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today [...]
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
16/10/2025
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the [...]
RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
16/10/2025
APOLLO BEACH, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. [OTCQB: RTGN] (“RetinalGenix” or the “Company”), a company developing ultra-high-resolution retinal imaging technology, today [...]
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads
16/10/2025
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads Financing led by Bpifrance with co-leads Kurma Partners, Andera Partners and [...]
Adcytherix lève 105 millions d’euros pour accélérer le développement de son portefeuille d‘anticorps conjugués de nouvelle génération intégrant de nouveaux agents cytotoxiques.
16/10/2025
Adcytherix lève 105 millions d’euros pour accélérer le développement de son portefeuille d‘anticorps conjugués de nouvelle génération intégrant de nouveaux agents cytotoxiques. Le tour de table est mené par Bpifrance, [...]
Aicuris Announces Pritelivir Met Primary Endpoint in Immunocompromised Patients with Refractory Herpes Simplex Virus in Phase 3 Pivotal Trial
16/10/2025
Pritelivir demonstrated clinically meaningful and highly statistically significant superiority (p=0.0047) in lesion healing up to 28 days of treatment, compared with standard-of-care (SoC) treatments in refractory [...]
Rakovina Therapeutics to Present New Data Highlighting Novel ATR Inhibitor with CNS Penetration at the AACR-NCI-EORTC International Conference
16/10/2025
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV, FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-enabled [...]
SAFE - Réalisation définitive de la réduction de capital non motivée par des pertes par voie de réduction de la valeur nominale des actions
16/10/2025
Réalisation définitive de la réduction de capital non motivée par des pertes par voie de réduction de la valeur nominale des actions Fleurieux-sur-l’Arbresle – France – 16 octobre 2025 - Safe (FR001400ZU25 – ALSAF) (la [...]

Pages